Proton pump inhibitors (PPIs) are among the most widely prescribed medications in clinical practice, primarily used for managing acid-related gastrointestinal disorders. While generally regarded as safe, with adverse effects being rare and typically mild, PPIs have been associated with hypersensitivity reactions. These reactions, which may be immediate or delayed, vary in severity from mild to potentially life-threatening.

This review provides an in-depth analysis of key aspects of PPI use, with a particular emphasis on the pathophysiological and clinical characteristics of both immediate and delayed hypersensitivity reactions. It also explores cross-reactivity among PPIs and offers a practical framework to assist clinicians in diagnosing and managing these conditions effectively. Additionally, the review highlights the critical need for further research to develop standardized diagnostic and therapeutic protocols, enabling personalized and evidence-based care for patients experiencing PPI-related hypersensitivity.

 

Proton pump inhibitors, hypersensitivity reactions, immediate hypersensitivity, delayed hypersensitivity, prick test, patch test, lymphocyte activation test, cross-reactivity

 

1. Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023 ;79(9):1159-72. doi: 10.1007/s00228-023-03534-z.
2. Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch. 2009;457(3):609-22. doi: 10.1007/s00424-008-0495-4.
3. Robinson LB, Ruffner MA. Proton pump inhibitors in allergy: benefits and risks. J Allergy Clin Immunol Pract. 2022;10(12):3117-23. doi: 10.1016/j.jaip.2022.09.022.
4. Bavbek S, Kepil Özdemir S, Bonadonna P, Atanaskovic-Markovic M, Barbaud A, Brockow K, et al. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper. Allergy. 2024;79(3):552-64. doi: 10.1111/all.15961.
5. Kepil Özdemir S, Bavbek S. Hypersensitivity reactions to proton-pump inhibitors: Clinical presentation, diagnosis, and management. Allergy Asthma Proc. 2020;41(2):e37-e44. doi: 10.2500/aap.2020.41.190033.
6. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66(2):273-80.
7. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528-34. doi: 10.1007/s11894-008-0098-4.
8. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25.
9. Gyawali CP. Proton pump inhibitors in gastroesophageal reflux disease: friend or foe. Curr Gastroenterol Rep. 2017;19(9):46. doi: 10.1007/s11894-017-0586-5.
10. Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S5. doi: 10.1186/ar4177.
11. Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2013;14(3):307-21. doi: 10.1517/14656566.2013.767332.
12. Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11(11):CD011194. doi: 10.1002/14651858.CD011194.pub3.
13. Reimer C, Bytzer P. Management of laryngopharyngeal reflux with proton pump inhibitors. Ther Clin Risk Manag. 2008;4(1):225-33. doi: 10.2147/tcrm.s6862.
14. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side effects of long-term proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol. 2018;123(2):114-21. doi: 10.1111/bcpt.13023.
15. Maideen NMP. Adverse effects associated with long-term use of proton pump Inhibitors. Chonnam Med J. 2023;59(2):115-27. doi: 10.4068/cmj.2023.59.2.115.
16. Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53(1):27-36. doi: 10.1007/s00535-017-1371-9.
17. Xie K, Li J, Tang C, Huang Z, Chen M. Association between proton pump inhibitors and dementia risk: a Mendelian randomization study. Sci Rep. 2024;14(1):28624. doi: 10.1038/s41598-024-79821-1.
18. Gao W, Huang Y, Lu S, Li C. The clinicopathological characteristics of gastric polyps and the relationship between fundic gland polyps, Helicobacter pylori infection, and proton pump inhibitors. Ann Palliat Med. 2021;10(2):2108-14. doi: 10.21037/apm-21-39.
19. Lai T, Wu M, Liu J, Luo M, He L, Wang X, et al. Acid-suppressive drug use during pregnancy and the risk of childhood asthma: a meta-analysis. Pediatrics. 2018;141(2):e20170889. doi: 10.1542/peds.2017-0889.
20. Mitre E, Susi A, Kropp LE, Schwartz DJ, Gorman GH, Nylund CM. Association between use of acid-suppressive medications and antibiotics during infancy and allergic diseases in early childhood. JAMA Pediatr. 2018;172(6):e180315. doi: 10.1001/jamapediatrics.2018.0315.
21. Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association between proton pump inhibitor use and risk of asthma in children. JAMA Pediatr. 2021;175(4):394-403. doi: 10.1001/jamapediatrics.2020.5710.
22. Pali-Schöll I, Jensen-Jarolim E. Anti-acid medication as a risk factor for food allergy. Allergy. 2011;66(4):469-77. doi: 10.1111/j.1398-9995.2010.02511.x.
23. Lombardo C, Bonadonna P. Hypersensitivity reactions to proton pump inhibitors. Curr Treat Options Allergy. 2015; 2:110–23. doi: 10.1007/s40521-015-0046-0
24. Baldo BA, Pham NH. Mechanisms of hypersensitivity. Drug Allergy. 2013; 3:37–90. doi: 10.1007/978-1-4614-7261-2_3.
25. Bose S, Guyer A, Long A, Banerji A. Evaluation and management of hypersensitivity to proton pump inhibitors. Ann Allergy Asthma Immunol. 2013;111(6):452-7. doi: 10.1016/j.anai.2013.08.022.
26. Bonadonna P, Lombardo C, Bortolami O, Bircher A, Scherer K, Barbaud A, et al. Hypersensitivity to proton pump inhibitors: diagnostic accuracy of skin tests compared to oral provocation test. J Allergy Clin Immunol. 2012;130(2):547-9. doi: 10.1016/j.jaci.2012.04.048.
27. Kepil Özdemir S, Yılmaz I, Aydin Ö, Büyüköztürk S, Gelincik A, Demirtürk M, et al. Immediate-type hypersensitivity reactions to proton pump inhibitors: usefulness of skin tests in the diagnosis and assessment of cross-reactivity. Allergy.2013;68(8):1008-14. doi: 10.1111/all.12189.
28. Mori F, Franceschini F, Saretta F, Bianchi A, Bottau P, Caimmi S, et al. Hypersensitivity reactions to proton pump inhibitors in childhood. Pediatr Allergy Immunol. 2020;31(Suppl 26):29-32. doi: 10.1111/pai.13345.
29. Kepil Özdemir S, Öner Erkekol F, Ünal D, Büyüköztürk S, Gelincik A, Dursun AB, et al. Management of hypersensitivity reactions to proton pump inhibitors: a retrospective experience. Int Arch Allergy Immunol. 2016;171(1):54-60. doi: 10.1159/000450952.
30. Kollmeier AP, Eddleston J, Zuraw BL, Christiansen SC. Recurrent anaphylaxis linked to pantoprazole. J Allergy Clin Immunol. 2004;114(4):975-7. doi: 10.1016/j.jaci.2004.05.068.
31. Lin CY, Wang CW, Hui CR, Chang YC, Yang CH, Cheng CY, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T-cell reactivity study. Allergy. 2018;73(1):221-9. doi: 10.1111/all.13235.
32. Spigariolo CB, Barei F, Maronese CA, Barberi F, Cattaneo A, Violetti SA. Three cases of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by proton-pump inhibitors. Australas J Dermatol. 2022;63(4):509-12. doi: 10.1111/ajd.13905.
33. Mumoli N, Luschi R, Camaiti A, Cei M, Bagnoni G, Biondi A. Severe exfoliative dermatitis caused by esomeprazole. J Am Geriatr Soc. 2011;59(12):2377-8. doi: 10.1111/j.1532-5415.2011.03711.x.
34. Rebuck JA, Rybak MJ, Ramos DP, Weingarten CM. Omeprazole-induced exfoliative dermatitis. Pharmacotherapy. 1998;18(4):877-9.
35. Chang YS. Hypersensitivity reactions to proton pump inhibitors. Curr Opin Allergy Clin Immunol. 2012;12(4):348-53. doi: 10.1097/ACI.0b013e328355b8d3.
36. Ghatan PH, Marcusson-Ståhl M, Matura M, Björkheden C, Lundborg P, Cederbrant K. Sensitization to omeprazole in the occupational setting. Contact Dermatitis. 2014;71(6):371-5. doi: 10.1111/cod.12305.
37. Al-Falah K, Schachter J, Sasseville D. Occupational allergic contact dermatitis caused by omeprazole in a horse breeder. Contact Dermatitis. 2014;71(6):377-8. doi: 10.1111/cod.12283.
38. Neumark M, Ingber A, Levin M, Slodownik D. Occupational airborne contact dermatitis caused by pantoprazole. Contact Dermatitis. 2011;64(1):60-1. doi: 10.1111/j.1600-0536.2010.01783.x.
39. Vilaplana J, Romaguera C. Allergic contact dermatitis due to lansoprazole, a proton pump inhibitor. Contact Dermatitis. 2001;44(1):47-8. doi: 10.1034/j.1600-0536.2001.440107-14.x.
40. Otani IM, Banerji A. Immediate and delayed hypersensitivity reactions to proton pump inhibitors: evaluation and management. Curr Allergy Asthma Rep. 2016;16(3):17. doi: 10.1007/s11882-016-0595-8.
41. Gouraud A, Vochelle V, Descotes J, Vial T. Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole. Clin Drug Investig. 2010;30(8):559-63. doi: 10.2165/11537230-000000000-00000.
42. Kallam A, Singla A, Silberstein P. Proton pump induced thrombocytopenia: a case report and review of literature. Platelets. 2015;26(6):598-601. doi: 10.3109/09537104.2014.953045.
43. Al-Nasser AN, Husain RS, Al-Marhabi AA. Proton pump inhibitors induce hemolytic anemia. J Family Med Prim Care. 2019;8(4):1486-7. doi: 10.4103/jfmpc.jfmpc_169_19.
44. Zeke A, Sudhir A. Management of allergic reactions and anaphylaxis in the emergency department. Emerg Med Pract. 2022;24(7):1-24.
45. Herszényi L, Bakucz T, Barabás L, Tulassay Z. Pharmacological approach to gastric acid suppression: past, present, and future. Dig Dis. 2020;38(2):104-11. doi: 10.1159/000505204.
46. Confino-Cohen R, Goldberg A. Anaphylaxis to omeprazole: diagnosis and desensitization protocol. Ann Allergy Asthma Immunol. 2006;96(1):33-6. doi: 10.1016/S1081-1206(10)61037-X.
47. Yıldız E, Çölkesen F, Sadi Aykan F, et al. Successful oral desensitization to rabeprazole: a case report of a patient with duodenal ulcer. Asthma Allergy Immunol. 2022; 20: 120-3.doi: 10.21911/aai.683.
48. Kumar R, Das A, Das S. Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: looking beyond guidelines! Indian J Dermatol. 2018;63(2):117-24. doi: 10.4103/ijd.IJD_583_17.
49. Copaescu A, Gibson A, Li Y, Trubiano JA, Phillips EJ. An updated review of the diagnostic methods in delayed drug hypersensitivity. Front Pharmacol. 2021;11:573573. doi: 10.3389/fphar.2020.573573.
50. Lin M, Gong T, Ruan S, Lv X, Chen R, Su X, et al. Emerging insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy. J Inflamm Res. 2024;17:2337-51. doi: 10.2147/JIR.S454673.